(Q83782089)
Statements
Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies (English)
P Schöffski
H Dumez
R Ruijter
B Miguel-Lillo